On January 27th, STENOCARE A/S (“STENOCARE” or “the Company”) announced that the Company has entered a strategic partnership with WEECO Pharma GmbH to launch premium medical cannabis oils in Germany. The first new product under the collaboration will be called “WEECO ASTRUM 10-10 extract” and will be available for patients during February 2026.
In summary, Analyst Group views STENOCARE’s partnership with WEECO Pharma and the launch of the WEECO ASTRUM 10-10 extract in Germany as a strategically important step to accelerate the commercialization of the Company’s premium Astrum oil. By leveraging WEECO’s established position, regulatory expertise, and sales and distribution capabilities in the German medical cannabis market, STENOCARE is expected to increase awareness, market penetration, and prescribing activity for Astrum oil. Germany represents one of the largest and most important medical cannabis markets in Europe, making a successful rollout a key value driver going forward.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on STENOCARE. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.